^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    IsoPSA®

    Company:
    Cleveland Diagnostics
    Type:
    Laboratory Developed Test
    Details
    Evidence
    News
    1year
    IsoPSA performance for detecting prostate cancer is unaffected by 5-ARI or α-blocker use. @EricKleinMD, @JasonScovell https://t.co/eqIRGegEXQ (@urogoldjournal)
    IsoPSA®
    1year
    As I understand, only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months. How is the 1% compared to chances of having prostate cancer for men above age of 50 that haven't been tested with Isopsa? ()
    Clinical
    |
    IsoPSA®